ClinicalTrials.gg
CompletedNCT00685802Updated Dec 22, 2009Results posted

Fasted Bioavailability Study of Cilostazol Tablets, 50mg

A Phase 1 interventional study of Cilostazol 50 mg Tablets and Cilostazol (Pletal®) 50 mg Tablets in Therapeutic Equivalency, Healthy, sponsored by Mutual Pharmaceutical Company, Inc.. Completed. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2009-12-22.

Sponsored by Mutual Pharmaceutical Company, Inc. · Phase 1 and Interventional

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
32
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

The purpose of this study is to evaluate and compare the relative bioavailability of a test formulation of cilostazol tablets to an equivalent dose of Pletal® (cilostazol) tablets after a single oral dose administered under fasting conditions.

Read the detailed description

The purpose of this study is to evaluate and compare the relative bioavailability of a test formulation of cilostazol tablets to an equivalent dose of Pletal® (cilostazol) tablets after a single oral dose administered under fasting conditions. Thirty-two non-smoking, non-obese, healthy male and female volunteers between the ages of 18 and 55 will be randomly assigned in a crossover fashion to receive each of two cilostazol dosing regimens in sequence with a 7 day washout period between dosing periods. On the morning of Day 1, after an overnight fast of at least 10 hours, subjects will receive either a single oral dose of the test formulation, cilostazol (2 x 50 mg tablets), or a single oral dose of the reference formulation, Pletal® (2 x 50 mg tablets). After a 7 day washout period on the morning of Day 8, following an overnight fast of at least 10 hours, subjects will receive the alternate regimen. Blood samples will be drawn from all participants before dosing and for 24 hours post-dose on a confined basis at times sufficient to adequately define the pharmacokinetics of cilostazol. Blood sampling will then continue on a non-confined basis at 36 and 48 hours post-dose. A further goal of this study is to evaluate the safety and tolerability of this regimen in healthy volunteers. Subjects will be monitored throughout the confinement portion of the study for adverse reactions to the study drug and/or procedures. Blood pressure and pulse will be measured before dosing and at 3 and 24 hours post-dose. All adverse events whether elicited by query, spontaneously reported, or observed by clinic staff will be evaluated by the investigator and reported in the subject's case report form.

02

Conditions studied

  • Therapeutic Equivalency, Healthy
03

In context

Lead sponsor

Mutual Pharmaceutical Company, Inc. is the lead sponsor of 44 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy adults 18-55 years of age
  • Non-smoking
  • Non-pregnant (, surgically sterile or using effective measures)
  • No more than 15% plus or minus from ideal weight for subject's height and elbow breadth as defined by the Metropolitan Life Insurance Company Statistical Bulletin. Extrapolations, if required, to be conducted according to BASi Standard Operating Procedures
  • Medically healthy on the basis of medical history and physical examination within 30 days prior to the start of the study
  • Test results from blood chemistry, hematology, and urinalysis performed within 30days prior to the start of the study within clinically acceptable limits
  • At screening, subjects must have blood pressure and pulse rate within the following ranges: Systolic blood pressure 90-140mmHg; Diastolic blood pressure 50-90mmHg; Pulse 45-100 bpm
  • An acceptable (EKG): sinus rhythm with no evidence of AV block or ischemic changes

Exclusion criteria

Exclusion Criteria:

  • Prescription drug use (excluding hormonal ) within 14 days prior to drug administration, each period
  • Aspirin ingestion within 7 days prior to drug administration, each period
  • Use of any over-the-counter preparations, herbal remedies, and/or nutritional supplements within 7 days prior to drug administration, each period
  • Consumption of grapefruit juice or grapefruit-containing products within 72 hours prior to drug administration , each period
  • Consumption of alcohol within 24 hours prior to drug administration, each period
  • Consumption of caffeine within 10 hours prior to drug administration, each period
  • Female subjects must not be pregnant or nursing; and must be surgically sterile; one year ; or on hormonal contraceptive agent(s), a diaphragm or condom with spermicidal foam or jelly, or IUD for at least three months prior to drug administration and agree to use the same method of contraception for at least 1 month after the last drug administration
  • Subjects with a history or presence of significant organ system (cardiovascular, neurological, hepatic, hematopoietic, renal, pulmonary, endocrine, or gastrointestinal) disorders, or ongoing infectious diseases
  • History of or adverse reactions to cilostazol (Pletal®), or other related drugs
  • Recent (12 month) history or evidence of alcoholism or drug abuse
  • Positive urine screening of drugs of abuse
  • Positive results to (HIV) or surface Antigen (HBsAg) tests
  • Participation in another clinical trial in the previous 30 days before day 1 of this study
  • Donation of blood in the previous 30 days before day 1 of this study
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 1
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
32 participants (actual)

Study arms

  • Experimental
    Cilostazol 50 mg Tablets

    A single dose of cilostazol (2 x 50 mg tablets) administered after an overnight fast of at least 10 hours.

    Drug: Cilostazol 50 mg Tablets

  • Experimental
    Cilostazol (Pletal® ) 50 mg Tablets

    A single dose of Cilostazol (Pletal® tablets, 2 x 50 mg ) administered after an overnight fast of at least 10 hours.

    Drug: Cilostazol (Pletal®) 50 mg Tablets

Interventions

06

What researchers measure

Primary outcomes

  1. Maximum Plasma Concentration (Cmax)

    The maximum or peak concentration that cilostazol (test and reference product) reaches in the plasma.

    Time frame: serial pharmacokinetic plasma concentrations were drawn prior to dose administration (0 hour) and at 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, 12, 16, 24, 36 and 48 hours after drug administration.

  2. Area Under the Concentration Versus Time Curve From Time 0 to Time t [AUC(0-t)]

    The area under the plasma concentration versus time curve, from time 0 to the time of the last measurable concentration (t), as calculated by the linear trapezoidal rule.

    Time frame: serial pharmacokinetic plasma concentrations were drawn prior to dose administration (0 hour) and at 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, 12, 16, 24, 36 and 48 hours after drug administration.

  3. Area Under the Concentration Versus Time Curve From Time 0 Extrapolated to Infinity [AUC(0-∞)]

    The area under the plasma concentration versus time curve from time 0 to infinity. AUC(0-∞) was calculated as the sum of AUC(0-t) plus the ratio of the last measurable plasma concentration to the elimination rate constant.

    Time frame: serial pharmacokinetic plasma concentrations were drawn prior to dose administration (0 hour) and at 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, 12, 16, 24, 36 and 48 hours after drug administration.

07

Results

Posted Dec 22, 2009

Participant flow

Thirty-two healthy adult male and female volunteers from the community-at-large were enrolled.

First Intervention
Participant flow — First Intervention
MilestoneCilostazol 50 mg Tablets Then Pletal® 50 mg TabletsPletal® 50 mg Tablets Then Cilostazol 50 mg Tablets
Started1616
Completed1616
Not completed00
Washout Period of 7 Days
Participant flow — Washout Period of 7 Days
MilestoneCilostazol 50 mg Tablets Then Pletal® 50 mg TabletsPletal® 50 mg Tablets Then Cilostazol 50 mg Tablets
Started1616
Completed1415
Not completed21
Withdrew: Protocol violation20
Withdrew: Withdrawal by subject01
Second Intervention
Participant flow — Second Intervention
MilestoneCilostazol 50 mg Tablets Then Pletal® 50 mg TabletsPletal® 50 mg Tablets Then Cilostazol 50 mg Tablets
Started1415
Completed1415
Not completed00

Outcome measures

PrimaryMaximum Plasma Concentration (Cmax)

The maximum or peak concentration that cilostazol (test and reference product) reaches in the plasma.

Time frame:
serial pharmacokinetic plasma concentrations were drawn prior to dose administration (0 hour) and at 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, 12, 16, 24, 36 and 48 hours after drug administration.
Reported as:
Mean · ng/mL
Maximum Plasma Concentration (Cmax)
ng/mLCilostazol 50 mg TabletsPletal® 50 mg Tablets
Maximum Plasma Concentration (Cmax)565.52 ± 155.67570.60 ± 174.72
PrimaryArea Under the Concentration Versus Time Curve From Time 0 to Time t [AUC(0-t)]

The area under the plasma concentration versus time curve, from time 0 to the time of the last measurable concentration (t), as calculated by the linear trapezoidal rule.

Time frame:
serial pharmacokinetic plasma concentrations were drawn prior to dose administration (0 hour) and at 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, 12, 16, 24, 36 and 48 hours after drug administration.
Reported as:
Mean · ng-hr/mL
Area Under the Concentration Versus Time Curve From Time 0 to Time t [AUC(0-t)]
ng-hr/mLCilostazol 50 mg TabletsPletal® 50 mg Tablets
Area Under the Concentration Versus Time Curve From Time 0 to Time t [AUC(0-t)]7,265.38 ± 1,975.877,354.03 ± 2,048.83
PrimaryArea Under the Concentration Versus Time Curve From Time 0 Extrapolated to Infinity [AUC(0-∞)]

The area under the plasma concentration versus time curve from time 0 to infinity. AUC(0-∞) was calculated as the sum of AUC(0-t) plus the ratio of the last measurable plasma concentration to the elimination rate constant.

Time frame:
serial pharmacokinetic plasma concentrations were drawn prior to dose administration (0 hour) and at 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, 12, 16, 24, 36 and 48 hours after drug administration.
Reported as:
Mean · ng-hr/mL
Area Under the Concentration Versus Time Curve From Time 0 Extrapolated to Infinity [AUC(0-∞)]
ng-hr/mLCilostazol 50 mg TabletsPletal® 50 mg Tablets
Area Under the Concentration Versus Time Curve From Time 0 Extrapolated to Infinity [AUC(0-∞)]8,641.26 ± 3,010.048,706.54 ± 3,142.36

Adverse events

Collected over All adverse events were recorded during the 14 day course of the study.. Non-serious events are listed at a 3.22% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cilostazol 50 mg Tablets—0/31 (0%)10/31 (32.3%)
Pletal® 50 mg Tablets—0/30 (0%)12/30 (40%)
Most frequent other events
Showing 10 of 17
Most frequent other events
EventCilostazol 50 mg TabletsPletal® 50 mg Tablets
HeadacheNervous system disorders6/315/30
HematuriaRenal and urinary disorders0/312/30
BradycardiaCardiac disorders0/311/30
TachycardiaCardiac disorders1/311/30
NauseaGastrointestinal disorders0/311/30
AnemiaBlood and lymphatic system disorders0/311/30
Anemia hypochromBlood and lymphatic system disorders0/311/30
AlbuminuriaMetabolism and nutrition disorders0/311/30
HyperglycemiaMetabolism and nutrition disorders1/311/30
ArthralgiaMusculoskeletal and connective tissue disorders0/311/30

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Cilostazol 50 mg Tablets and Pletal® 50 mg Tablets
<=18 years0
Between 18 and 65 years32
>=65 years0
Age Continuous
Age Continuous(years)Cilostazol 50 mg Tablets and Pletal® 50 mg Tablets
Mean32.25 ± 11.98
Sex: Female, Male
Sex: Female, Male(Participants)Cilostazol 50 mg Tablets and Pletal® 50 mg Tablets
Female14
Male18
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Cilostazol 50 mg Tablets and Pletal® 50 mg Tablets
American Indian or Alaska Native0
Asian1
Native Hawaiian or Other Pacific Islander0
Black or African American26
White5
More than one race0
Unknown or Not Reported0
08

Study locations

No study locations are listed for this record.

09

References and documents

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2004, a primary completion of Jul 2004 and a completion of Jul 2004. It does not say whether these dates are actual or estimated.

Results were first posted in Dec 2009, 5 years 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 24, 2008
First posted
May 28, 2008
Start
Jun 2004
Primary completionActual
Jul 2004
CompletionActual
Jul 2004
Results first posted
Dec 22, 2009
Last update
Dec 22, 2009
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 22, 2009, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00685802
First posted
May 28, 2008
Start date
Jun 2004
Primary completion
Jul 2004
Completion
Jul 2004
Results posted
Dec 22, 2009
Last update
Dec 22, 2009

Study contacts

Dilip K Guha-Ray, M.D.
principal investigator · BASi Baltimore Clinical Research Unit

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2009. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cilostazol

Start the discussion